Kim, Sung-Sik
(Division of Cardiology, Department of Internal Medicine, The Catholic University of Korea School of Medicine)
Jeon, Hui-Kyung (Division of Cardiology, Department of Internal Medicine, The Catholic University of Korea School of Medicine) Cho, Gyu-Min (Division of Cardiology, Department of Internal Medicine, The Catholic University of Korea School of Medicine) Lee, Jong-Hwan (Division of Cardiology, Department of Internal Medicine, The Catholic University of Korea School of Medicine) Kim, Soo-Jung (Division of Cardiology, Department of Internal Medicine, The Catholic University of Korea School of Medicine) Park, Mi-Youn (Division of Cardiology, Department of Internal Medicine, The Catholic University of Korea School of Medicine) Lee, Seung-Jae (Division of Cardiology, Department of Internal Medicine, The Catholic University of Korea School of Medicine) Shim, Byung-Ju (Division of Cardiology, Department of Internal Medicine, The Catholic University of Korea School of Medicine) Lee, Dong-Hyeon (Division of Cardiology, Department of Internal Medicine, The Catholic University of Korea School of Medicine) Shin, Woo-Seung (Division of Cardiology, Department of Internal Medicine, The Catholic University of Korea School of Medicine) Lee, Jong-Min (Division of Cardiology, Department of Internal Medicine, The Catholic University of Korea School of Medicine) Youn, Ho-Joong (Division of Cardiology, Department of Internal Medicine, The Catholic University of Korea School of Medicine) |
1 | Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction, Experimental observations and clinical implications. Circulation 1990;81:1161-72. DOI ScienceOn |
2 | St John Sutton M, Pfeffer MA, Plappert T, Rouleau JL, Moyé LA, Dagenais GR, Lamas GA, Klein M, Sussex B, Goldman S, et al. Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction. The protective effects of captopril. Circulation 1994;89:68-75. DOI |
3 | Francis GS. Pathophysiology of chronic heart failure. Am J Med 2001; 110 Suppl 7A:37S-46S. DOI |
4 | Gaudron P, Eilles C, Kugler I, Ertl G. Progressive left ventricular dysfunction and remodeling after myocardial infarction. Potential mechanisms and early predictors. Circulation 1993;87:755-63. DOI |
5 | Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown EJ Jr, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992;327: 669-77. DOI ScienceOn |
6 | Harada K, Sugaya T, Murakami K, Yazaki Y, Komuro I. Angiotensin II type 1A receptor knockout mice display less left ventricular remodeling and improved survival after myocardial infarction. Circulation 1999;100: 2093-9. DOI |
7 | Patel AR, Konstam MA. Recent advances in the treatment of heart failure. Circ J 2002;66:117-21. DOI ScienceOn |
8 | Dickstein K, Kjekshus J; OPTIMAAL Steering Committee of the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 2002;360:752-60. DOI |
9 | Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Kober L, Maggioni AP, Solomon SD, Swedberg K, Van de Werf F, White H, Leimberger JD, Henis M, Edwards S, Zelenkofske S, Sellers MA, Califf RM; Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003;349: 1893-906. DOI ScienceOn |
10 | Kim YS, Cho HK, Chung IM, Park SH, Park SH, Shin GJ. Changes in LV mass, LV morphology and diastolic function of LV in response to antihypertensive treatment. J Korean Soc Echocardiogr 1997;5:154-63. |
11 | Tani S, Nagao K, Anazawa T, Kawamata H, Furuya S, Takahashi H, Iida K, Matsumoto M, Kumabe N, Onikura M, Hirayama A. Effects of enalapril and losartan in left ventricular remodeling after acute myocardial infarction: a possible mechanism of prevention of cardiac events by angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in high-risk myocardial infarction. Intern Med 2009;48:877-82. DOI ScienceOn |
12 | Rim SJ, Chung NS, Lee NH, Goh CW, Ha JW, Kim JY, Oh EK, Ahn SK, Kim TY, Lee MH, Jang YS, Shim WH, Cho SY, Kim SS. Dobutamine echocardiography in the prediction of left ventricular remodeling after acute myocardial infarction. J Korean Soc Echocardiogr 1997;5: 85-93. |
13 | ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. Lancet 1995;345:669-85. DOI |
14 | GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico. Lancet 1994;343:1115-22. |
15 | Solomon SD, Skali H, Anavekar NS, Bourgoun M, Barvik S, Ghali JK, Warnica JW, Khrakovskaya M, Arnold JM, Schwartz Y, Velazquez EJ, Califf RM, McMurray JV, Pfeffer MA. Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarction. Circulation 2005;111:3411-9. DOI ScienceOn |
16 | Frangogiannis NG, Smith CW, Entman ML. The inflammatory response in myocardial infarction. Cardiovasc Res 2002;53:31-47. DOI ScienceOn |
17 | Anzai T, Yoshikawa T, Shiraki H, Asakura Y, Akaishi M, Mitamura H, Ogawa S. C-reactive protein as a predictor of infarct expansion and cardiac rupture after a first Q-wave acute myocardial infarction. Circulation 1997; 96:778-84. DOI |
18 | Maekawa Y, Anzai T, Yoshikawa T, Sugano Y, Mahara K, Kohno T, Takahashi T, Ogawa S. Effect of granulocyte-macrophage colony-stimulating factor inducer on left ventricular remodeling after acute myocardial infarction. J Am Coll Cardiol 2004;44:1510-20. DOI ScienceOn |
19 | Kumar AG, Ballantyne CM, Michael LH, Kukielka GL, Youker KA, Lindsey ML, Hawkins HK, Birdsall HH, MacKay CR, LaRosa GJ, Rossen RD, Smith CW, Entman ML. Induction of monocyte chemoattractant protein-1 in the small veins of the ischemic and reperfused canine myocardium. Circulation 1997;95:693-700. DOI |
20 | Hayasaki T, Kaikita K, Okuma T, Yamamoto E, Kuziel WA, Ogawa H, Takeya M. CC chemokine receptor-2 deficiency attenuates oxidative stress and infarct size caused by myocardial ischemia-reperfusion in mice. Circ J 2006;70:342-51. DOI ScienceOn |
21 | Hayashidani S, Tsutsui H, Shiomi T, Ikeuchi M, Matsusaka H, Suematsu N, Wen J, Egashira K, Takeshita A. Anti-monocyte chemoattractant protein-1 gene therapy attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 2003;108: 2134-40. DOI ScienceOn |
22 | Dewald O, Zymek P, Winkelmann K, Koerting A, Ren G, Abou- Khamis T, Michael LH, Rollins BJ, Entman ML, Frangogiannis NG. CCL2/Monocyte Chemoattractant Protein-1 regulates inflammatory responses critical to healing myocardial infarcts. Circ Res 2005;96:881-9. DOI ScienceOn |
23 | Kohno T, Anzai T, Naito K, Sugano Y, Maekawa Y, Takahashi T, Yoshikawa T, Ogawa S. Angiotensin-receptor blockade reduces border zone myocardial monocyte chemoattractant protein-1 expression and macrophage infiltration in post-infarction ventricular remodeling. Circ J 2008;72:1685-92. DOI ScienceOn |